---
figid: PMC4743050__nihms-729689-f0006
figtitle: 'Targeting RAS-mutant cancers: is ERK the key?'
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Canis lupus familiaris
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4743050
filename: nihms-729689-f0006.jpg
figlink: /pmc/articles/PMC4743050/figure/F6/
number: F6
caption: Second generation RAF inhibitors such as vemurafenib and dabrafenib are BRAF-selective
  and cause paradoxical activation of ERK (panel (a)). The inhibitor-blocked BRAF
  forms a heterodimer with active CRAF and complexes with activated RAS. MEK inhibitors
  transiently block ERK activation. Since high ERK activation can be deleterious for
  cell proliferation, ERK activation stimulates negative feedback mechanisms that
  dampen upstream signaling through the pathway (panel (b)). Kinome reprogramming
  results in rewiring of the signaling networks to increase flux through non-RAF-MEK-ERK
  pathways such as PI3K-AKT-mTOR.
papertitle: 'Targeting RAS-mutant cancers: is ERK the key?.'
reftext: Meagan B. Ryan, et al. Trends Cancer. ;1(3):183-198.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9687598
figid_alias: PMC4743050__F6
figtype: Figure
redirect_from: /figures/PMC4743050__F6
ndex: 95c19af9-dec8-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4743050__nihms-729689-f0006.html
  '@type': Dataset
  description: Second generation RAF inhibitors such as vemurafenib and dabrafenib
    are BRAF-selective and cause paradoxical activation of ERK (panel (a)). The inhibitor-blocked
    BRAF forms a heterodimer with active CRAF and complexes with activated RAS. MEK
    inhibitors transiently block ERK activation. Since high ERK activation can be
    deleterious for cell proliferation, ERK activation stimulates negative feedback
    mechanisms that dampen upstream signaling through the pathway (panel (b)). Kinome
    reprogramming results in rewiring of the signaling networks to increase flux through
    non-RAF-MEK-ERK pathways such as PI3K-AKT-mTOR.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Hras
  - Kras
  - Rem1
  - Braf
  - Braf-rs1
  - Raf1
  - Pik3r1
  - Mdk
  - Akt1
  - Ephb2
  - Mapk1
  - Mtor
  - KRAS
  - HRAS
  - NRAS
  - BRAF
  - RAF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - MTOR
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Dsor1
  - Mtk
  - Akt
  - Erk7
  - rl
  - Tor
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
